A global phase III ClarIDHy trial of Tibsovo (ivosidenib), sponsored by Agios Pharmaceuticals Inc., in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 mutation met its primary endpoint.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe